Home > Insider Trading > Filing (0001179110-20-004869)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235010	Momenta Pharmaceuticals Inc	MNTA	Biological Products, (No Disgnostic Substances) (2836)	043561634

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1798748	Agnieszka Cieplinska	C/O Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142	Chief Accounting Officer (Pao)	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-04-12	3,150	$0.00	4,082	No	4	A	Direct
Common Stock	Disposition	2020-04-14	921	$29.57	3,161	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Acquisiton	2020-04-12	3,150	$0.00	3,150	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,150			No	4	A	Direct

Footnotes

Shares received pursuant to settlement of Performance Stock Units that were granted on April 12,2019.
Includes 932 shares acquired under the issuer's employee stock purchase plan at a price of $9.76 per share on January 31, 2020.
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock.
Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021.